Budget 2018-19

There are several candidates in the works – the Serum Institute of India,  Bharat Biotech , and Zydus Cadila are working on either developing or manufacturing anti-malarial vaccines Vaccines for malaria and dengue, tropical mosquito-borne infections, could take two to four years to hit the Indian market, say industry insiders. At present, there are several candidates in the works with the Serum Institute of India (SII), Bharat Biotech, and Zydus Cadila all working on either developing or manufacturing anti-malarial vaccines. As for dengue, French firm Sanofi and Japan’s Takeda are looking to bring their vaccines here. SII, the world’s largest vaccine maker, and Novavax are collaborating for phase-3 clinical trials of the Oxford University’s Jenner Institute’s  malaria vaccine  on over 4,800 children in four African countries. It has shown 77 per cent efficacy in trials on infants, the first vaccine to cross the World Health Organization’s (WHO) target of 75 per cent effic...

  Japan’s Takeda Pharmaceutical is looking at making vaccines a core business after completing asset sales to lower debt following its takeover of Shire, Chief Executive Christophe Weber said TOKYO (Reuters) – Japan’s Takeda Pharmaceutical Co is looking at making vaccines a core business after completing asset sales to lower debt following its takeover of Shire Plc, Chief Executive Christophe Weber said. Japan’s biggest drugmaker by revenue recently completed $10 billion in sales of mostly over-the-counter drug assets to reduce debt after its $59 billion purchase of Shire, saying it would focus on five key business areas. With a dengue fever vaccine in development and deals to make and distribute  COVID-19 vaccines  in Japan, the company could add a new pillar to its business lineup, Weber said. “We are in the vaccines business,” Weber told Reuters in an interview. “If the dengue vaccine is successful, yes, it would be a sixth one.” Takeda’s current five core businesses a...